Astellas' VEOZAH™ (fezolinetant) Approved by U.S. FDA for Treatment of Vasomotor Symptoms Due to Menopause

 VEOZAH is first-in-class treatment option to reduce the frequency and severity of moderate to severe VMS due to menopause
TOKYO, May 12, 2023 /PRNewswire/ -- Astellas Pharma Inc. today... | June 14, 2023

Related Keywords

Canada ,United States ,Tokyo ,Japan ,Northbrook ,Queensland ,Australia ,Switzerland ,Genevieve Neal Perry ,Naoki Okamura ,Astellas Pharma ,Prnewswire Astellas Pharma Inc ,Health Qual Life Outcomes ,Elsevier ,School Of Medicine Department Obstetrics ,Astellas Pharma Inc ,J Public Health ,Drug Administration ,Astellas Inc ,Head Of Biopharma Development ,Full Interactive Multimedia ,Medicine Department ,Marci English ,Vice President ,Biopharma Development ,Astella New Drug Application ,Provides Update ,Fezolinetant New Drug Application ,Prescribing Information ,Patient Product Information ,Focus Area Approach ,Equal Life ,Penn Ovarian Aging Study ,